GlassScriptPhysician profile
Matthew P Mene
NPI 1184687097
$250,283.39
in general payments reported to CMS, 2019-2025
62 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $22K · 2021: $14K · 2022: $31K · 2023: $22K · 2024: $64K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Consulting Fee: $20K · Food and Beverage: $15K · Travel and Lodging: $9,766 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,476.75 |
| Consulting Fee | $19,749.47 |
| Food and Beverage | $14,889.36 |
| Travel and Lodging | $9,765.56 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $109,338.63 | 2019-2025 | Erleada, Akeega, Carvykti |
| Astellas Pharma US INC | $52,200.61 | 2019-2025 | Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $46,466.22 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $10,037.24 | 2019-2025 | Provenge |
| Pfizer INC. | $9,151.47 | 2019-2025 | |
| Myovant Sciences INC. | $3,980.17 | 2021-2022 | |
| Avyxa Pharma, LLC | $3,565.12 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,662.63 | 2021-2025 | Imfinzi, Lynparza |
| Janssen Scientific Affairs, LLC | $1,847.50 | 2022-2024 | Erleada |
| Astellas Pharma Global Development | $1,440.00 | 2023 | Xtandi |
| Janssen Global Services, LLC | $1,010.00 | 2019 | |
| Urogen Pharma, INC. | $790.88 | 2022-2025 | Jelmyto |
| Verity Pharmaceuticals INC. | $692.90 | 2021-2025 | Trelstar |
| Antares Pharma, INC. | $518.12 | 2019-2025 | Xyosted |
| Sumitomo Pharma America, INC. | $421.89 | 2023-2025 | Gemtesa, Orgovyx |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.